

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

<p>The following potential equality issues were identified during the scoping process:</p>
--

- | |
|---|
| <ul style="list-style-type: none">• Inequality of access to LDL-apheresis due to high set up costs for treatment and few established centres with appropriate expertise• Injection only treatment which will exclude people who will not accept injection based therapies, including many from ethnic minority groups. |
|---|

<p>The potential equality issues identified during the scoping process have been noted by the Committee. None of these issues related to protected characteristics, as defined by the Equalities Act, and so were not considered equality issues.</p>

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No potential equality issues were raised in the submissions, expert statements or ERG report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No other potential equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The Committee's considerations of equality issues are included in the summary table at the end of the appraisal consultation document.

Approved by Associate Director (name): ...Frances Sutcliffe

Date: 01/02/2016

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

The following potential equality issue was identified during the consultation:

- people of Ashkenazi Jewish origin may need life-enhancing and life-saving drugs for hypercholesterolemia

The committee considered a potential equality issue that the incidence of familial hypercholesterolaemia could be higher in people of Ashkenazi Jewish origin. It concluded that its recommendations for alirocumab would apply to all patients and that the recommendations would not have a different impact on people protected by the equality legislation compared with the wider population.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations have changed, but they do not make it more difficult for a specific group to access the technology compared with other groups.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's considerations of equality issues are described in section 4.21 and the 'Summary of appraisal committee's key conclusions' of the final appraisal determination.

Approved by Centre or Programme Director (name): ...Meindert Boysen.....

Date: 28 April 2016

